These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 2352480

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR, Moriarty RJ, Mayer JH.
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [Abstract] [Full Text] [Related]

  • 43. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS, Hohman TC, Millen J.
    J Med Chem; 1994 Jun 24; 37(13):2043-58. PubMed ID: 8027986
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat.
    Stevens MJ, Lattimer SA, Feldman EL, Helton ED, Millington DS, Sima AA, Greene DA.
    Metabolism; 1996 Jul 24; 45(7):865-72. PubMed ID: 8692023
    [Abstract] [Full Text] [Related]

  • 46. Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozocin-diabetic rat.
    Greene DA, Lewis RA, Lattimer SA, Brown MJ.
    Diabetes; 1982 Jul 24; 31(7):573-8. PubMed ID: 7160537
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H.
    Diabetes; 1987 Jan 24; 36(1):6-13. PubMed ID: 3025043
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
    Tomlinson DR, Mayer JH.
    Exp Neurol; 1985 Aug 24; 89(2):420-7. PubMed ID: 2410289
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
    Price DE, Airey CM, Alani SM, Wales JK.
    Diabetes; 1988 Jul 24; 37(7):969-73. PubMed ID: 3133261
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.